The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.
Wolfgang Wick
Consultant or Advisory Role - Antisense Pharma; Magforce; MSD; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; Lilly; MSD
Christoph Meisner
No relevant relationships to disclose
Michael Platten
Honoraria - Merck Serono
Research Funding - Bayer Schering Pharma; Merck Serono
Matthias Simon
No relevant relationships to disclose
Guido Nikkhah
No relevant relationships to disclose
Kirstin Papsdorf
No relevant relationships to disclose
Michael Sabel
Consultant or Advisory Role - Magforce
Christian Braun
No relevant relationships to disclose
Guido Reifenberger
Consultant or Advisory Role - MSD
Honoraria - MSD
Michael Weller
Consultant or Advisory Role - Merck Serono; MSD; Roche
Honoraria - Merck Serono; Merck Sharp & Dohme; Roche
Research Funding - Merck Serono